Skip to main content

Meet Ana Palmeire-de-Oliveira, Winner of the NeuEve Award for Best Contribution in Vulvo-Vaginitis Research!


From left to right:
Prof. Dr. Ljubomir Petricevic of Austria, Medical University of Vienna,
Ana Palmeire-de-Oliveira, University of Beira Interior,
Prof. Dr. Gilbert Donders of Belgium, President of ISIDOG

Congratulations to Ana Palmeira-de-Oliveira, for her important contribution to vulvo-vaginitis research!

Ana was awarded a travel scholarship from NeuEve for her journal article published in European Journal of Pharmaceutical Sciences.

NeuEve is very proud and we feel blessed to be able to support young scientists, especially in the extremely important field of woman's health!

She wrote the article: Vaginal semisolid products: Technological performance considering physiologic parameters

Here's the abstract:

Vaginal semisolid products are frequently used to treat vaginal infections and atrophy-related symptoms of menopause.

Formulations composition and the methods for their characterization, especially those developed concerning the target epithelia, are key tools to predict in vivo results at early stages of product development.

However, recent studies on this subject have been almost exclusively focused on anti-HIV preparations.

The aim of this work consists on improving traditional characterization methods by using physiological parameters in order to construct predictive tools to characterize a new ideal vaginal semisolid formulation whatever target it may have.

Ten vaginal antimicrobial and hormonal products already available in the market were studied (Gino-Canesten®, Sertopic®, Dermofix®, Gyno-pevaryl®, Lomexin®, Gino Travogen®, Dalacin V®, Ovestin®, Blissel®, Colpotrophine®).

Furthermore, Universal Placebo gel and Replens® were used for comparison.

Products were characterized in terms of: pH and buffering capacity in a vaginal fluid simulant (VFS); osmolality - directly and upon dilution in VFS; textural parameters (firmness, adhesiveness and bioadhesion) using vaginal ex vivo porcine epithelium; and viscosity (including VFS dilution at 37 °C and after administration on an ex vivo model).

Interestingly, the majority of the tested commercial vaginal formulations did not present technological characteristics close to the ideal ones when tested under target biological conditions.

The inclusion of such methodologic adaptations is expected to optimize cost-efficiency of new formulations development by predicting efficacy and safety profiles at early stages of product development.

© 2017 Elsevier B.V. All rights reserved.

Comments

Popular posts from this blog

Posterior Fourchette Fissures, Simply Explained

What is the Posterior Fourchette? The Posterior Fourchette is located at bottom of your vaginal entrance. It is a thin tissue fold and should be able to stretch during sexual intercourse. What is a Posterior Fourchette Fissure and what causes it? If you are approaching menopause, you may have had an OB-GYN exam and felt some sharp pain. You doctor may have told you that you have a Posterior Fourchette Fissure. The main cause for most posterior fourchette fissures is atrophic vulvovaginitis. Other causes of posterior fourchette fissures include yeast infections, lichen sclerosis, and eczema. How does Atrophic Vulvovaginitis affect the Posterior Fourchette? When you are a young healthy woman, sexual activity is usually OK. When you are reaching menopause, your hormone levels drop. Lots of women then experience vaginal dryness. First it can feel like sand paper. As atrophy is progressing, the vaginal tissues start to shrink. Finally, the vaginal entrance could become as tiny …

Stephanie Prima with a heartfelt review of NeuEve

Holistic health mentor Stephanie Prima recently wrote about a heartfelt topic: her personal sexual health and how NeuEve has helped. NeuEve is nothing short of brilliant! Here's more: "I’m creating this post to be as open and honest as I possibly can be about a topic that I have never yet heard anyone talk about. Doctors don’t even have a viable solution for this condition. So it’s scary to make myself this vulnerable. But I trust that my words will once again inspire others. My condition reached a point where inserting anything was too painful and my partner didn’t want to inflict any more on me. While I was emotionally willing and wanting, my body simply couldn’t. For some women, these conditions can result in decreased sensations or libido as well. From this understanding, it’s no wonder so many women entering menopause have little sexual desire. They talk about hot flashes and weight gain, but the rest of the symptoms are simply too embarrassing to admit. I actually fe…

Female Libido and Sexual Dysfunction

Hot Flashes Female Sexual Dysfunction Once women enter menopause, they often talk loudly about hot flashes and night sweats. The elephant in the room is loss of libido. Interest or desire for sex declines. Some women are unable to become aroused, while others cannot achieve orgasm. Moreover, vaginal dryness and atrophy, as well as painful sex, can also result in a loss of libido. The incidence of female sexual dysfunction is high, about 40% among normal aging postmenopausal women and close to 100% among breast cancer survivors who have been on an anti-hormonal therapy. Female sexual dysfunction can have a profound impact on quality of life, but it has been largely ignored by the healthcare community. Major reasons may include: traditional social conservatism, gender inequality, and cultural suppression against women’s sexual desire. Because truly effective remedies are not available, even if women openly seek care for sexual dysfunction, they are often given ineffective treatment…